Disease · EFO_0009833

kidney injury

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. kidney injury. Diseases, record EFO_0009833. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/EFO_0009833

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: kidney injury; Open Targets
Open Targets ID: EFO_0009833; Open Targets
Other names: injury to kidney; Open Targets
NCI Thesaurus: C35245; NCI Thesaurus
Highest stage of its drugs: Phase 3, for 2 of its 8 drugs, from ClinicalTrials.gov; Open Targets

Drugs8

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
ISOFLURANE	CHEMBL1256	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
XENON	CHEMBL1236802	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
OXYGEN	CHEMBL1234886	Small molecule	Phase 2/3	ClinicalTrials.gov	1	1	1	Drugs and targets
AMINOPHYLLINE	CHEMBL1370561	Protein	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets
DEXMEDETOMIDINE	CHEMBL778	Small molecule	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets
MYCOPHENOLATE MOFETIL	CHEMBL1456	Small molecule	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets
REMIFENTANIL	CHEMBL1005	Small molecule	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets
TACROLIMUS	CHEMBL3989887	Small molecule	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets

Targets40

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
ADORA1	Adenosine receptor	1	Adenosine receptor antagonist	Unknown	https://conductscience.org/library/genes/134	Drugs and targets
ADORA2A	Adenosine receptor	1	Adenosine receptor antagonist	Unknown	https://conductscience.org/library/genes/135	Drugs and targets
ADORA2B	Adenosine receptor	1	Adenosine receptor antagonist	Unknown	https://conductscience.org/library/genes/136	Drugs and targets
ADORA3	Adenosine receptor	1	Adenosine receptor antagonist	Unknown	https://conductscience.org/library/genes/140	Drugs and targets
ADRA2A	Adrenergic receptor alpha-2	1	Adrenergic receptor alpha-2 agonist	Unknown	https://conductscience.org/library/genes/150	Drugs and targets
ADRA2B	Adrenergic receptor alpha-2	1	Adrenergic receptor alpha-2 agonist	Unknown	https://conductscience.org/library/genes/151	Drugs and targets
ADRA2C	Adrenergic receptor alpha-2	1	Adrenergic receptor alpha-2 agonist	Unknown	https://conductscience.org/library/genes/152	Drugs and targets
FKBP1A	Peptidyl-prolyl cis-trans isomerase FKBP1A	1	FK506-binding protein 1A inhibitor	Unknown	https://conductscience.org/library/genes/2280	Drugs and targets
GABRA1	GABA-A receptor; anion channel	1	GABA-A receptor; anion channel positive allosteric modulator	Phase 3	https://conductscience.org/library/genes/2554	Drugs and targets
GABRA2	GABA-A receptor; anion channel	1	GABA-A receptor; anion channel positive allosteric modulator	Phase 3	https://conductscience.org/library/genes/2555	Drugs and targets

1 to 10 of 40

See all 40 targets

Trials5

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02361944	Risk of Oxygen During Cardiac Surgery Trial	Phase 2/3	213	2023-08-14	Cardiac Surgery	OXYGEN	Its record names the disease	ClinicalTrials.gov
NCT01759862	Perioperative Aminophylline to Improve Early Kidney Function After a Kidney Transplant	Not applicable	50	2019-03-05	Function of Renal Transplant	AMINOPHYLLINE	Its record names the disease	ClinicalTrials.gov
NCT00970073	Low Dose Thymoglobulin to Protect Kidney Function After Liver Transplant	Not applicable	30	2018-10-09	Liver Transplantation	MYCOPHENOLATE MOFETIL, TACROLIMUS	Its record names the disease	ClinicalTrials.gov
NCT01839084	PaNeX: Partial Nephrectomy Under Xenon	Phase 3	46		Renal Function After Partial Nephrectomy	ISOFLURANE, XENON	Its record names the disease	ClinicalTrials.gov
NCT07094165	The Effects of Dexmedetomidine and Remifentanil on Kidney Injury After Muscle Compression Injury in Rats	Not applicable	28		Acute Kidney Injury, Crush Injury, Rhabdomyolysis	DEXMEDETOMIDINE, REMIFENTANIL	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials10

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Normoxia vs Hyperoxia: Number of People With Arrhythmia	37 of 100	46 of 100	200	NCT02361944	Trial comparisons
Normoxia vs Hyperoxia: Respiratory Failure	5 of 100	1 of 100	200	NCT02361944	Trial comparisons
Normoxia vs Hyperoxia: Acute Brain Dysfunction (Delirium)	16 of 100	22 of 100	200	NCT02361944	Trial comparisons
Normoxia vs Hyperoxia: deaths from any cause	2 of 100	0 of 100	200	NCT02361944	Trial comparisons
Normoxia vs Hyperoxia: Acute Kidney Injury, According to KDIGO Criteria	21 of 100	21 of 100	200	NCT02361944	Trial comparisons
Normoxia vs Hyperoxia: Number of People With Stroke	1 of 100	2 of 100	200	NCT02361944	Trial comparisons
Normoxia vs Hyperoxia: serious adverse events	8 of 100	11 of 100	200	NCT02361944	Trial comparisons
Aminophylline vs Control: deaths from any cause	0 of 23	0 of 27	50	NCT01759862	Trial comparisons
Aminophylline vs Control: serious adverse events	0 of 23	0 of 27	50	NCT01759862	Trial comparisons
Aminophylline vs Control: Presence of Fibrosis Measured on Protocol Biopsy	11 of 23	14 of 26	49	NCT01759862	Trial comparisons

Papers from its trials16

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
34761118	RESULT	1	PubMed
32317860	RESULT	1	PubMed
28331287	RESULT	1	PubMed
27598600	RESULT	1	PubMed
25613736	RESULT	1	PubMed
25010612	RESULT	1	PubMed
24907872	RESULT	1	PubMed
23657066	RESULT	1	PubMed
23347808	RESULT	1	PubMed
20783577	RESULT	1	PubMed

1 to 10 of 16

See all 16 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/EFO_0009833

GET https://conductscience.org/api/diseases/v1/EFO_0009833/targets?page=2

API reference For AI assistants